Xenon Impairs Neurocognitive and Histologic Outcome after Cardiopulmonary Bypass Combined with Cerebral Air Embolism in Rats

Bettina Jungwirth, M.D.,* M. Lucia Gordan, M.D.,* Manfred Blobner, M.D.,† Wolfgang Schmehl, Ph.D.,‡ Eberhard F. Kochs, M.D., † G. Burkhard Mackensen, M.D.§

Background: The neuroprotective properties of xenon may improve cerebral outcome after cardiac surgery using cardiopulmonary bypass (CPB). However, its disposition to expand gaseous bubbles that during CPB present as cerebral air emboli (CAE) could abolish any beneficial effect or even worsen cerebral outcome. Therefore, the authors studied the impact of xenon on neurologic, cognitive, and histologic outcome after CPB combined with CAE in rats.

Methods: With institutional review board approval, 40 rats were assigned to four groups (n = 10). In two CPB-CAE groups, rats were subjected to 90 min of normothermic CPB with 10 repetitively administered CAEs (0.3 µl/bolus). Rats in two sham groups were not exposed to CPB and CAE. Groups were further subdivided into xenon (56%; 20 min before, during, and 30 min after CPB) and nitrogen groups. Neurologic and cognitive function was tested until postoperative day 14, when cerebral infarct volumes were determined.

Results: Animals of the CPB-CAE groups showed transient deficits in gross neurologic function. Further, rats of the CPB-CAE-xenon group demonstrated impaired fine motor and cognitive performance persisting until postoperative day 14. Consistently, infarct volumes were larger in the CPB-CAE-xenon group compared with the CPB-CAE-nitrogen group (P = 0.03).

Conclusions: This is the first demonstration in which the neurologic effects of CAE have been examined in a rat model of CPB. Xenon exposure aggravated the neurologic dysfunction that is produced by CAE during CPB; potential neuroprotective effects of xenon may have been masked by the effects of xenon on CAE.

SINCE the anesthetic properties of the noble gas xenon have been recognized in the middle of the past century, ¹ xenon has been characterized as an almost ideal anesthetic. Besides its safety and efficacy profile described in

This article is featured in "This Month in Anesthesiology." Please see this issue of ANESTHESIOLOGY, page 5A.

Received from the Klinik für Anaesthesiologie, Technische Universität München, Klinikum rechts der Isar, Munich, Germany. Submitted for publication July 19, 2005. Accepted for publication December 20, 2005. Supported by AGA AB, Linde Gas Therapeutics, Lidingö, Sweden. Presented at the 100th Annual Meeting of the American Society of Anesthesiologists, Atlanta, Georgia, October 22-26, 2005. For this work, B. Jungwirth was awarded the third prize at the Resident Research Essay Contest at the 2005 Annual Meeting of the American Society of Anesthesiologists, Atlanta, Georgia.

Address correspondence to Dr. Mackensen: Department of Anesthesiology, Division of Cardiothoracic Anesthesiology and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina 27710. b.mackensen@ duke.edu. Individual article reprints may be purchased through the Journal Web site, www.anesthesiology.org.

noncardiac surgery,2 xenon offers cardiovascular stability,³⁻⁵ pharmacokinetic benefits with rapid induction and recovery of anesthesia, and profound analgesia.^{6,7} Recently, xenon has been shown to provide neuroprotective properties in both in vitro as well as in vivo studies, most likely *via N*-methyl-D-aspartate receptor antagonism.⁸⁻¹¹ Clinically, these properties have not been tested, although it would be of particular interest to administer xenon to patients at risk for perioperative cerebral injuries such as cardiac surgery patients undergoing cardiopulmonary bypass (CPB). 12,13 However, recent in vitro and in vivo studies have shown that xenon may expand enclosed gas spaces such as the microbubbles that are both entrained as well as generated within the CPB circuit. 14-16 Therefore, it cannot be excluded that xenon may worsen neurologic injury from cerebral air embolism (CAE). High numbers of CAEs are known to be present in most cardiac surgery procedures and have been implicated as one of several contributors (hypoperfusion, atheromatous emboli, and others) to postoperative cognitive impairment.¹⁷ Consequently, xenon's disposition to expand air bubbles may abolish any neuroprotective effect or even amplify neurologic injury after CPB with CAE. The current study was designed to investigate the safety of xenon application in the presence of CAE using a long-term recovery model of CPB in rats. In preparation for this study, we identified a suitable volume for CAE during CPB that allows longterm recovery of rats in the presence of neurologic deficits. 18

The aims of the current study were to determine (1) whether xenon anesthesia during CPB combined with CAE influences neurologic, cognitive, and behavioral long-term outcome and (2) whether xenon alters histologic outcome in this context.

Materials and Methods

All animals were treated in compliance with the Principles of Laboratory Animal Care formulated for the National Society for Medical Research¹⁹ and the Guide for the Care and the Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources.²⁰ Experimental protocols were approved by the institutional animal care committee (Regierung von Oberbayern, Munich, Germany).

Four experimental groups were investigated (n = 10per group) in a randomized fashion: Rats in the CPB-CAE

^{*} Resident in Anesthesia, † Professor of Anesthesiology, Klinik für Anaesthesiologie, Technische Universität München, Klinikum rechts der Isar, Munich, peutics, Lidingö, Sweden. § Associate Professor of Anesthesiology, Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.

groups were subjected to 90 min of normothermic CPB with 10 repetitively administered CAEs, whereas rats in the sham-operated groups were exposed to the same surgical preparation and anesthesia but were neither connected to CPB nor received CAE. Groups were further subdivided into xenon (56% xenon, 5% N₂, 34% O₂, and 5% CO₂) and nitrogen (61% N₂, 34% O₂, and 5% CO₂) groups with the accordant mixture inhaled 20 min before CPB, during, and 30 min after CPB or to equivalent times in the sham-operated groups.

Surgical Preparation and Cardiopulmonary Bypass Nonfasted male Sprague-Dawley rats from Charles River Laboratories (363 ± 17 g, 10 weeks old; Sulzfeld, Germany) were cannulated for CPB as previously reported.²¹ Briefly, the tail artery was cannulated for aortic inflow, the right external jugular vein was cannulated for venous return, and the right superficial caudal epigastric artery was cannulated for monitoring of mean arterial blood pressure. The corresponding vein was cannulated for drug administration. All rats were ventilated with the same closed-circuit gas-delivery system, and inspiratory xenon concentrations were measured using a thermal conductivity sensor (provided by AGA AB, Lidingö, Sweden). For the injection of CAE, a PE-10 catheter (PE-10, Intramedic; Becton Dickinson GmbH, Heidelberg, Germany) was inserted via the stump of the right external carotid artery and advanced into the internal carotid artery just beyond the pterygopalatine branch, which was ligated.²² During surgery, anesthesia was maintained with 1.5-2.0% isoflurane and repetitive fentanyl boluses (5 μ g). Pericranial temperature was monitored and controlled to 37.5°C (HYP-1 Newport, Santa Ana, CA). This temperature was selected based on previous work examining xenon during experimental CPB in rats.9

After completion of surgery, animals were denitrogenated, and the gas mixture was adjusted according to group assignment (56% xenon, 5% $\rm N_2$, 34% $\rm O_2$, and 5% $\rm CO_2$ in xenon groups and 61% $\rm N_2$, 34% $\rm O_2$ and 5% $\rm CO_2$ in nitrogen groups). This gas mixture was applied 20 min before CPB, during CPB, and 30 min after CPB and for equivalent times in the sham groups. Concomitantly, the anesthetic regimen was changed to intravenous midazolam (0.4 mg/kg), fentanyl (30 $\mu \rm g/kg)$ and atracurium (0.5 mg/kg) as a bolus injection, followed by a mixed continuous infusion (2.5 $\mu \rm g \cdot kg^{-1} \cdot min^{-1}$ fentanyl, 0.03 mg $\cdot kg^{-1} \cdot min^{-1}$ midazolam, and 0.084 mg $\cdot kg^{-1} \cdot min^{-1}$ atracurium) and was sustained until the end of the CPB.

The CPB circuit consisted of a venous reservoir, a peristaltic pump (Masterflex®; Cole-Parmer Instrument Co., Vernon Hills, IL), a custom-designed membrane oxygenator, an in-line flow probe (2N806 probe and T208 flowmeter; Transonics Systems, Inc., Ithaca, NY), and an arterial inflow cannula. The CPB circuit was primed with 14 ml whole blood obtained from one heparinized

(150 U/rat) donor rat and 2 ml hetastarch, 6%. One hundred units of heparin was added to the prime. CPB-CAE animals were subjected to 90 min of normothermic nonpulsatile CPB with flow rates of 160-180 ml \cdot min⁻¹ \cdot kg⁻¹. For the entire CPB period, ventilation of the lungs was discontinued. After 90 min of CPB, the animals were weaned from CPB without the need for inotropic support. The heparin anticoagulation was allowed to dissipate spontaneously without administration of protamine. Glucose, bicarbonate, and calcium were administered if required. After decannulation, rats remained anesthetized (continuous infusion of 3.9 μ g · kg⁻¹ · min⁻¹ fentanyl, 0.048 mg · $kg^{-1} \cdot min^{-1}$ midazolam, and 0.129 mg $\cdot kg^{-1} \cdot min^{-1}$ atracurium), intubated, and ventilated for 1 h. After resuming spontaneous ventilation and extubation, the animals were recovered in an oxygen-enriched environment for 12 h with free access to water and food. On the first postoperative day, rats were returned to their hole-board cages and housed in familiar groups. The sham-operated groups had all CPB catheters left in place for 90 min (thereby mimicking the CPB protocol) but were not connected to the CPB circuit itself. Sham animals were decannulated and recovered in the same fashion as the CPB-CAE animals.

Cerebral Air Embolism

Rats subjected to 90 min of normothermic CPB received 10 equally sized CAEs (0.3 µl/single bolus) via the right internal carotid artery. The choice of $0.3 \mu l$ per bolus was based on preliminary work showing that this size of CAE during CPB is associated with a mortality rate of 1% (95% confidence interval, 0.1-14.5%) and an incidence of neurologic deficits of 85.8% (95% confidence interval, 40.7-98.2%).18 The first embolus was administered at 15 min of CPB, and the last embolus was administered at 75 min of CPB. Using a Hamilton syringe (10-µl Gastight® No. 1701N; Hamilton Bonaduz AG, Bonaduz, Switzerland), the size of the air bubble could be exactly determined by the placement of the air between 5-µl saline aliquots. At the end, 10 µl saline was injected to flush the last air bubble into the cerebral circulation. The shamoperated animals received saline (10 μ l) instead of CAE.

Neurologic and Neurocognitive Testing

All neurologic, cognitive, and behavioral tests were performed by an investigator blinded to treatment. Rats were housed under standard laboratory conditions (12 h light-12 h dark, lights on at 0:30 AM, 22°C, 60% humidity, and free access to water and standard rat chow) 3 weeks before the experiments to acclimate to the changed day-night rhythm. Nine days before surgical preparation, animals were housed in the modified hole-board environment for habituation.

On the preoperative as well as on the 1st, 2nd, 3rd, and 12th postoperative days, animals underwent standardized functional neurologic testing performed as previJUNGWIRTH *ET AL.*

Table 1. Physiologic Data during the Operative Procedure in the Four Groups Studied

	Preparation	Treatment	Before CPB	45 min CPB	90 min CPB	1 h after CPB
Mean arterial pressure, mmHg	Sham	Air	101 ± 18	130 ± 11	126 ± 11	131 ± 15
	Sham	Xenon	84 ± 8*	127 ± 13	129 ± 17	131 ± 14
	CPB	Air	92 ± 10	88 ± 22*†	75 ± 14*†	123 ± 18
	CPB	Xenon	82 ± 14*	71 ± 15*†	76 ± 11*†	115 ± 17
Hemoglobin concentration, mg/dl	Sham	Air	13.5 ± 0.3	13.6 ± 0.5	13.6 ± 0.8	13.0 ± 0.6
	Sham	Xenon	13.2 ± 0.6	13.1 ± 0.6	13.0 ± 0.5	12.2 ± 0.9
	CPB	Air	13.5 ± 0.9	11.4 ± 0.6*†	$11.2 \pm 0.7*\dagger$	$11.7 \pm 0.6^*$
	CPB	Xenon	13.2 ± 0.8	11.2 ± 0.3*†	11.2 ± 0.4*†	$11.7 \pm 0.7^*$
Paco ₂ , mmHg	Sham	Air	35.5 ± 4.4	33.0 ± 2.9	35.6 ± 2.0	36.7 ± 2.4
	Sham	Xenon	41.8 ± 3.1*	39.2 ± 1.1*	$39.9 \pm 2.4^*$	33.0 ± 4.1
	CPB	Air	$33.2 \pm 4.0 \pm$	38.0 ± 2.4*	39.0 ± 3.0*	37.4 ± 3.1
	CPB	Xenon	38.3 ± 3.8	$38.3 \pm 3.5^*$	$39.1 \pm 2.5^*$	34.4 ± 4.8
Pao ₂ , mmHg	Sham	Air	125 ± 16	136 ± 13	131 ± 15	231 ± 53
	Sham	Xenon	117 ± 14	125 ± 10	122 ± 14	281 ± 43
	CPB	Air	126 ± 14	179 ± 21*†	160 ± 27*†	208 ± 60†
	CPB	Xenon	124 ± 23	191 ± 13*†	173 ± 14*†	180 ± 45†

Variables were obtained before cardiopulmonary bypass (before CPB), at 45 min of CPB (45 min CPB), at 90 min of CPB (90 min CPB), and 1 h after CPB (1 h after CPB) or at equivalent times in the sham-operated groups (sham). Values are presented as mean \pm SD. Rats subjected to CPB demonstrate lower mean arterial pressure, lower hemoglobin concentrations, and higher arterial oxygen tension (Pao₂) during CPB than sham groups. Before CPB, mean arterial pressure in the two xenon groups was lower compared with the sham-nitrogen group, probably because of the additional anesthesia effect of xenon. Higher arterial carbon dioxide tension (Paco₂) levels in the two xenon groups compared with the nitrogen groups before CPB and lower Paco₂ levels in the sham-nitrogen group compared with all other groups during CPB were detected, but there were no differences in Paco₂ between the two CPB groups during CPB.

ously described including assays of prehensile traction and balance beam performance.²³ Sensorimotor function was evaluated using an established protocol,²⁴ which included movement symmetry, body proprioception, and response to vibrissae touch. In addition, fine motor skills and cognitive and behavioral function were assessed using the modified hole-board test according to an established protocol.^{25,26} Briefly, the rats lived in an area divided into a home cage ($80 \times 60 \times 50$ cm) and a test arena ($40 \times 60 \times 50$ cm), with the hole-board ($20 \times$ 40 cm) placed in the middle of the test arena. Fifteen holes covered by lids were staggered on the board. After opening, coil springs force the lids back to their original position. Three holes, baited with puffed rice, were marked with white tape. All holes were flavored with black currant aroma to cover odor and smell of the puffed rice.

On the 2nd and 3rd postoperative days, animals were habituated to the hole board and to the puffed rice. Beginning with the 4th postoperative day, rats learned the test procedure over 6 consecutive days (learning period). After a resting period of 4 days, memory function was assessed on the 14th postoperative (retest). Animals were tested in the modified hole-board test for three trials daily. The sequence of marked holes was randomly changed every day.

Two fine motor parameters were investigated using the modified hole-board test: (1) Impairments in motor dexterity were assumed if rats were unable to empty a correct visited hole, and (2) impairments in fine motor skills were assumed if the time needed for food intake was extended. Three cognitive parameters were evaluated: (1) Deficits in overall cognitive performance were assumed if the time required to complete one trial was extended; (2) deficits within the declarative memory were assumed if rats visited nonbaited holes or did not visit baited holes, referred to as wrong choice; and (3) deficits within the working memory were assumed if rats revisited a baited hole, referred to as repeated choice.²⁵ In addition, rat behavior, such as motivation, anxiety, and exploration, was assessed with the modified hole-board test.

Histologic Examination

On postoperative day 14, animals were anesthetized with 5% isoflurane and subjected to in situ brain fixation. The brains was removed in toto, were serially cut (10- μ m sections) at 150- μ m intervals, and were stained with hematoxylin and eosin. Infarct volume was determined by digitally sampling stained sections with a video camera controlled by an image analyzer. With the observer blinded to experimental conditions, infarct borders in the cortex and the subcortex were individually outlined using an operator-controlled cursor, and consequently, infarct area was calculated automatically. Infarct volumes were computed as running sums of infarct area multiplied by the known interval (e.g., 150 μ m) between sections over the extent of the infarct expressed as an orthogonal projection. In addition, the number of single infarcts was recorded.

Statistical Analysis

Physiologic, neurologic, cognitive, and behavioral values were analyzed using general linear models with the

^{*} P < 0.05 compared with sham-air group. † P < 0.05 compared with sham-xenon group. ‡ P < 0.05 compared with CPB-xenon group.





Fig. 1. Gross neurologic function of rats preoperatively (day -1) and at various times after cardiopulmonary bypass (CPB) combined with cerebral air embolism (CAE) and sham operation with xenon or nitrogen inhalation. Prehensile traction (time at rope; A) was transiently impaired in the two CPB-CAE groups but not in the sham groups (P = 0.026), with no differences among groups at postoperative day 12 (P > 0.05). Balance performance (time on beam; B) was impaired in both CPB-CAE groups with recovery to baseline at postoperative day 12 (P =0.001; post boc P > 0.05). Sensorimotor function is displayed as score value (C). A score up to 1 indicates normal performance. Score values were higher (worse) in rats subjected to CPB and CAE (P < 0.001) and in rats anesthetized with xenon (P =0.032). Although all animals improved over time, higher score values persisted in rats of the CPB-CAE-xenon group at postoperative day 12 (P < 0.001).

between-group factors preparation (CPB-CAE vs. sham) and treatment (xenon vs. nitrogen), the within-group factor time, and their interaction terms. Values were analyzed $post\ boc$ using factorial analysis of variance followed by Bonferroni t tests. Physiologic values were $post\ boc$ analyzed at each time; neurologic, cognitive, and behavioral variables were analyzed on the final post-operative day (day 12 for neurologic and day 14 for cognitive and behavioral values). Histologic values were compared using the Student t test.






Fig. 2. Fine motor function of rats at various times after cardio-pulmonary bypass (CPB) combined with cerebral air embolism (CAE) and sham operation with xenon or nitrogen inhalation. Motor dexterity (number of correct hole visits without food intake; A) was impaired in the CPB-CAE-xenon group (P < 0.001). The impaired dexterity in the CPB-CAE-xenon group did not improve over time and persisted at postoperative day 14 (P = 0.024). Fine motor skills (time needed for food intake; B) were affected after CPB with CAE (P = 0.027) and following xenon anesthesia (P = 0.042). This impairment improved over time, and *post boc* analyses did not reveal any differences at postoperative day 14 (P > 0.05).

Results

Two animals were excluded from further data analysis because of postoperative development of cervical hematoma with inspiratory stridor (one animal in the CPB-CAE-nitrogen group and one animal in the CPB-CAE-xenon group). These two rats were replaced to keep sample size equal.

Hemodynamic and Physiologic Data

Table 1 displays the physiologic values of rats after CPB with CAE or sham operation. Rats subjected to CPB and CAE demonstrated lower mean arterial pressure, lower hemoglobin concentrations, and higher arterial oxygen tension during CPB than sham groups, most likely because of the nature of CPB. During CPB and CAE, there were no differences in physiologic values between the CPB-CAE-xenon group and the CPB-CAE-nitrogen group. The rats' body weight decreased more in the CPB-CAE groups compared with the sham groups, with a nadir on postoperative day 6 (P = 0.007).

774 JUNGWIRTH *ET AL*.




Fig. 3. Neurocognitive function of rats at various times after cardiopulmonary bypass (CPB) combined with cerebral air embolism (CAE) and sham operation with xenon or nitrogen inhalation. Overall cognitive performance (time needed to complete the test; A) was impaired after CPB–CAE–xenon (P < 0.001), did not improve over time, and persisted at postoperative day 14 (post boc P = 0.007). Declarative memory (number of wrong choices; B) was impaired in rats of the CPB–CAE–xenon group (P = 0.002), with no differences among groups at postoperative day 14 (P > 0.05). Working memory (number of repeated choices; C) was comparable among groups (P > 0.05).

Neurologic, Cognitive, and Behavioral Assessment

Gross neurologic function was impaired in all animals subjected to CPB and CAE on the first postoperative days. Further, animals exposed to xenon during CPB and CAE demonstrated sensorimotor and fine motor deficits that persisted for at least 2 weeks (figs. 1 and 2). Rats of the CPB-CAE-xenon group demonstrated a worse neurocognitive outcome compared with the remaining groups until postoperative day 14 (fig. 3). No differences in behavior were detected during the observation period. Therefore, differences in neurologic and neurocognitive outcomes cannot be attributed to altered behavior.

Histologic Results

None of the sham-operated rats demonstrated any infarct. All of the rats subjected to CPB and CAE showed at least one infarct in the cortex of the right hemisphere. Larger infarcts involved the striatum and hippocampus, and one rat (CPB-CAE-xenon group) demonstrated an infarct that extended into the left hemisphere. In animals exposed to CPB and CAE, xenon resulted in larger infarct volumes and a higher number of infarcts (fig. 4).


Discussion

The "inert" gaseous anesthetic xenon caused a significant increase in ischemic brain damage when administered perioperatively in a combined model of CPB and CAE in rats. This effect was evident both histologically and functionally in rats allowed to survive 14 days after CPB and CAE. Xenon increased cerebral infarct size and worsened motor as well as neurocognitive performance. Although theoretical models and *in vitro* studies in aqueous solution have outlined xenon's potential to expand air bubbles, this study describes the first *in vivo* setting that allowed investigation of the safety profile of xenon inhaled during CPB in the presence of CAE. ^{14,15}

The effects of xenon in the context of CPB and CAE were studied for several reasons. First, xenon's use in patients undergoing CPB for cardiac surgery has been suggested because of its anesthetic qualities and its attractive hemodynamic profile. Second, it has been demonstrated that xenon possesses protective properties in both experimental myocardial and cerebral injury. 10,27 More recently, xenon has also been shown to provide neuroprotection in a rat model of CPB.9 Third, despite xenon's abundant advantages, it may also have some significant disadvantages in the setting of cardiac surgery. Xenon's low solubility makes it theoretically more likely to augment gaseous microbubbles that, during cardiac surgery with CPB, present as CAEs. Because CAEs are thought to contribute at least to perioperative cognitive decline after cardiac surgery, 17 any augmentation by xenon may increase the risk of cerebral injury and must be weighed against its previously well-documented neuroprotective effects. The investigation of this safety aspect seems to be particularly important before considering xenon in those cardiac surgery settings that are known to expose patients to higher numbers of CAEs, such as open-chamber procedures.

In the past, several animal models of CAE have been established and provide important insights into the kinetics of CAE with respect to variation in pial arteriole diameters, changes in cerebral blood flow, and alterations in somatosensory evoked potentials after different volumes of CAE. ^{22,28} The combination of CPB and CAE for the investigation of the effects of CAE on cerebral outcome was first described by Hindman *et al.* ²⁹ Al-

Fig. 4. Histologic outcome 14 days after cardiopulmonary bypass (CPB) combined with cerebral air embolism (CAE) with xenon or nitrogen inhalation. Mean total infarct volume (sum of single infarcts; A) was larger in rats of the CPB-CAE-xenon group (82.7 \pm 16.2 mm³) compared with rats of the CPB-CAE-nitrogen group (33.2 \pm 19.1 mm³; P = 0.032). Animals exposed to CPB-CAE-xenon demonstrated a higher number of infarcts (n = 4.6 \pm 0.6; B) than animals of the CPB-CAE-nitrogen group (n = 3.1 \pm 0.6; P = 0.045).



though their model in rabbits offered a valid approach, certain limitations remained, such as the lack of suitable tests for neurocognitive assessment and difficulties with long-term survival of the animals. Combining a previously described technique of selective cerebroarterial injection of air emboli with an established model of CPB in rats, we aimed to overcome these limitations. Therefore, the current study presents the primary description of a long-term recovery model of CPB combined with CAE in rats that allowed us to investigate the effect of xenon on long-term neurologic and neurocognitive outcome in this context.

Recently, xenon has been shown to attenuate CPB-induced neurologic and neurocognitive deficits in rats. These neuroprotective properties seem to be offset by the effects of xenon on CAE in the current study. Larger infarct volumes, together with a worsened functional outcome in animals exposed to xenon, may foster safety concerns regarding the disposition of xenon to expand air bubbles. Of interest, xenon anesthesia also resulted in a higher number of detected infarcts. One can only speculate that xenon, by altering the bubble volume or absorption kinetics of CAE, may have led to prolonged occlusion of a given brain territory, which then resulted in the redirection of blood flow into adjacent brain regions. This may then have produced further infarction due to the redistribution of CAE. Neurologic and neuro-

cognitive performance were assessed using the modified hole-board test, a unique test battery that allows a comprehensive and detailed evaluation of cerebral outcome in rats. This test offers a sensitive testing environment allowing the assessment of a variety of cognitive, fine motor, and behavioral parameters in only one test. Further, this test battery allowed a complete evaluation of neurologic performance from the first postoperative day until day 14. In addition, behavior aspects such as anxiety and motivation were determined, because it is well known that these parameters can influence cognitive function. ²⁵

Even though this model was established to mimic clinical standards as closely as possible, some important limitations remain. First, we chose to inject the CAE directly into the cerebral circulation to ensure standardized and controlled CAE. Clinically, CAEs are generated within the CPB circuitry or are entrained during open-chamber procedures and reach the cerebral circulation *via* the aortic cannula. Second, the generation of a shower of CAEs as detected in the operating room by means of transcranial Doppler techniques would have been preferable, but because of technical limitations and the miniaturization of this model, only 10 equally sized CAEs were administered. Third, the study was restricted to the investigation of a certain embolus size (0.3 μ I) that was shown to generate neurologic deficits in the major-

776 JUNGWIRTH *ET AL.*

ity of rats as evaluated in a pilot study. ¹⁸ It remains unclear whether the CAE size/damage ratio described herein is relevant for the clinical setting. That is, it is uncertain whether xenon would exert similar effects on cerebral outcomes in humans undergoing CPB for cardiac surgery. Last, median sternotomy, direct cardiac cannulation, and surgery were not performed, to allow long-term survival of the animals.

In summary, if CAE occurs during xenon exposure in a rat model of CPB, fine motor, cognitive, and histologic outcomes are impaired. Potential neuroprotective properties of xenon, as recently revealed in a rat model of CPB, may have been masked by the effects of xenon on CAE. Use of xenon for its neuroprotective potential may have to be restricted in cardiac surgical procedures where similar CAE size/damage ratio occurs.

The authors thank Anja Berkmann, D.V.M. (Resident, Klinik für Anaesthesiologie, Technische Universität München, Klinikum rechts der Isar, Munich, Germany), for neurocognitive and behavioral testing of the animals; Kristine Kellermann, D.V.M. (Resident, Klinik für Anaesthesiologie, Technische Universität München, Klinikum rechts der Isar, Munich, Germany), for histologic analyses; and John Dingley, M.B. Ch.B. (Consultant Anesthetist, Department of Anesthetics, Morriston Hospital, Swansea, United Kingdom), for providing a closed xenon delivery system.

References

- 1. Cullen SC, Gross EG: The anesthetic properties of xenon in animals and human beings with additional observations on krypton. Science 1951; 113:580-2
- 2. Goto T, Nakata Y, Morita S: Will xenon be a stranger or a friend? The cost, benefit, and future of xenon anesthesia. Anesthesiology 2003; 98:1-2
- 3. Dingley J, King R, Hughes L, Terblanche C, Mahon S, Hepp M, Youhana A, Watkins A: Exploration of xenon as a potential cardiostable sedative: A comparison with propofol after cardiac surgery. Anaesthesia 2001; 56:829–35
- 4. Luttropp H, Romner B, Perhag L, Eskilsson J, Fredriksen S, Werner O: Left ventricular performance and cerebral haemodynamics during xenon anaesthesia. Anaesthesia 1993; 48:1045-9
- 5. Hettrick DA, Pagel PS, Kersten JR, Tessmer JP, Bosnjak ZJ, Georgieff M, Warltier DC: Cardiovascular effects of xenon in isoflurane-anesthetized dogs with dilated cardiomyopathy. Anesthesiology 1998; 89:1166-73
- 6. Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S: Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anesthesiology 1997; 86:1273-8
- 7. Nakata Y, Goto T, Saito H, Ishiguro Y, Terui K, Kawakami H, Tsuruta Y, Niimi Y, Morita S: Plasma concentration of fentanyl with xenon to block somatic and hemodynamic responses to surgical incision. Anesthesiology 2000; 92:1043-8
- 8. Ma D, Wilhelm S, Maze M, Franks NP: Neuroprotective and neurotoxic properties of the "inert" gas, xenon. Br J Anaesth 2002; 89:739-46

- 9. Ma D, Yang H, Lynch J, Franks NP, Maze M, Grocott HP: Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology 2003; 98:690-8
- 10. Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, Grocott HP: The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anexthesiology 2003: 99:876-81
- 11. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR: How does xenon produce anaesthesia? (letter). Nature 1998; 396:324
- 12. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA: Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 2001; 344:395-402
- 13. Wolman RL, Nussmeier NA, Aggarwal A, Kanchuger MS, Roach GW, Newman MF, Mangano CM, Marschall KE, Ley C, Boisvert DM, Ozanne GM, Herskowitz A, Graham SH, Mangano DT: Cerebral injury after cardiac surgery: Identification of a group at extraordinary risk. Stroke 1999; 30:514–22
- 14. Lockwood G: Expansion of air bubbles in aqueous solutions of nitrous oxide or xenon. Br J Anaesth 2002; 89:282-6
- 15. Sta Maria N, Eckmann DM: Model predictions of gas embolism growth and reabsorption during xenon anesthesia. Anesthesiology 2003; 99:638-45
- 16. Grocott HP, Sato Y, Homi HM, Smith BE: The influence of xenon, nitrous oxide and nitrogen on gas bubble expansion during cardiopulmonary bypass. Eur J Anaesthesiol 2005; 22:353-8
- 17. Stump DA, Rogers AT, Hammon JW, Newman SP: Cerebral emboli and cognitive outcome after cardiac surgery. J Cardiothorac Vasc Anesth 1996; 10:113-8
- 18. Jungwirth B, Blobner M, Schmehl W, Kochs EF, Mackensen GB: Does xenon affect neurologic outcome and mortality following cardiopulmonary bypass combined with cerebral air embolism in the rat? (abstract). Anesthesiology 2004; 101:A-867
- 19. National Society for Medical Research: Principles of Laboratory Animal Care
- 20. Institute of Laboratory Animal Resources: Guide for the Care and the Use of Laboratory Animals. NIH Publication No. 86-23. Bethesda, MD: National Institutes of Health, revised 1985
- 21. Mackensen GB, Sato Y, Nellgard B, Pineda J, Newman MF, Warner DS, Grocott HP: Cardiopulmonary bypass induces neurologic and neurocognitive dysfunction in the rat. Anesthesiology 2001; 95:1485-91
- 22. Furlow TW Jr: Experimental air embolism of the brain: An analysis of the technique in the rat. Stroke 1982; 13:847-52
- 23. Combs DJ, D'Alecy LG: Motor performance in rats exposed to severe forebrain ischemia: Effect of fasting and 1,3-butanediol. Stroke 1987; 18:503-11
- 24. Garcia J, Wagner S, Liu K, Hu X: Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: Statistical validation. Stroke 1995; 26:627–35
- $25.\,$ Ohl F, Roedel A, Storch C, Holsboer F, Landgraf R: Cognitive performance in rats differing in their inborn anxiety. Behav Neurosci 2002; $116:\!464-\!71$
- 26. Ohl F, Holsboer F, Landgraf R: The modified hole board as a differential screen for behavior in rodents. Behav Res Methods Instrum Comput 2001; 33:392-7
- 27. Preckel B, Ebel D, Mullenheim J, Frassdorf J, Thamer V, Schlack W: The direct myocardial effects of xenon in the dog heart $in\ vivo$. Anesth Analg 2002; 94:545–51s
- 28. Helps S, Meyerwitting M, Reilly P, Gorman D: Increasing doses of intracarotid air and cerebral blood flow in rabbits. Stroke 1990; 21:1340-5
- 29. Hindman BJ, Dexter F, Enomoto S, Subieta A, Smith T, Cutkomp J: Recovery of evoked potential amplitude after cerebral arterial air embolism in the rabbit: A comparison of the effect of cardiopulmonary bypass with normal circulation. Amstriesiology 1998; 88:696–707